Japan approves Vectura's inhaler capsules
28th Sep 2012 13:12
Shares of Cambridge-based Vectura rose after it confirmed the Japanese government has approved its Seebri inhalation capsules used in inhaler devices. The treatment, which will be available to patients and physicians in Japan by year-end, will trigger a £2.5m milestone payment for Vectura from its
Read moreVectura reaches new milestone in VR315 project
15th Aug 2012 13:39
Vectura Group, a pharma company specialising in treatments for respiratory diseases, has recorded revenues of three million dollars under an agreement signed a year ago for the development, manufacturing and commercialisation of VR315 with an international pharmaceutical company. The revenue total
Read moreTuesday broker round-up
24th Apr 2012 09:27
ARM Holdings: Nomura maintains neutral rating and 600p target. Associated British Foods: Nomura keeps buy stance and 1,325p target; Jefferies mains hold recommendation and 1,155p target. Barclays: Investec maintains buy rating and 240p target. BBA Aviation: Jefferies keeps buy rating and 250p tar
Read moreDrug trial success boosts Vectura
24th Apr 2012 09:05
Vectura, the pharma company specialising in treatments for respiratory diseases, says a trial of one of its development drugs has shown better results than the main competitor. The not-catchily titled QVA149 is a treatment delivered through an inhaler, mainly targeted at chronic obstructive pulmona
Read moreVectura study reaches end point of third phase of study
2nd Apr 2012 11:34
Drug developer Vectura has announced that the first three QVA149 Phase III studies in the treatment of chronic obstructive pulmonary disease (COPD) all met their primary endpoints. The results demonstrate the potential of the product as a treatment for COPD. Chief Executive Dr Chris Blackwell sa
Read moreNew Homeserve director opens account
10th Feb 2012 15:23
A non-executive director of FTSE 250 emergency repair group Homeserve has purchased his first lot of shares one month after joining the firm. Ben Mingay, who joined the board at the start of January, bought himself 20,000 at 250.70p for a total of £50,140. The purchase comes just days after the s
Read moreVectura trims R&D spend for fiscal 2011/12
11th Jan 2012 12:54
Vectura Group, the company that specialises in the treatment of respiratory diseases, is reducing its research and development (R&D) expenditure by around £1m during the final quarter of 2012. The firm now expects R&D costs for the full year to 31 March 2012 to be around £33m, while full year reve
Read moreWednesday broker round-up - UPDATE
11th Jan 2012 08:56
Unilever: Bank of America Merrill Lynch downgrades to underweight from neutral. Aggreko: Credit Suisse downgrades to neutral from outperform. Capita: Citi upgrades to buy from neutral. Reckitt Benckiser: Morgan Stanley upgrades to overweight from neutral. Rentokil: RBC upgrades to top-pick fr
Read moreBroker tips: Vectura Group, Intermediate Capital Group, BT Group
25th Nov 2011 12:08
Analysts at Singer Capital write today that, "NVA237 (COPD) has been filed with Japanese regulators by Vectura's development partner Novartis. In addition Vectura has highlighted a respiratory-based copromotion agreement between Novartis and Japanese company Eisai, whereby the latter will help marke
Read moreBroker snap: Singer Capital reiterates outperform on Vectura
25th Nov 2011 11:54
Analysts at this broker write today that, "NVA237 (COPD) has been filed with Japanese regulators by Vectura's development partner Novartis. In addition Vectura has highlighted a respiratory-based copromotion agreement between Novartis and Japanese company Eisai, whereby the latter will help market b
Read moreFriday broker round-up: Atkins WS, Johnson Matthey, BT
25th Nov 2011 09:58
Atkins WS: UBS reiterates neutral, raises price target to 600p from 560p. Johnson Matthey: UBS reiterates buy, ups target to 2015p from 1915p. Lloyds: UBS reiterates buy, lowers target to 55p from 60p. BT Group: Credit Suisse reiterates outperform. Intermediate Capital Group: Credit Suisse reite
Read moreHammerson directors go shopping
10th Aug 2011 12:44
Two senior board members at Hammerson have both bought shares in the shopping centre operator, buying into weakness after a recent plummet in profits. Chief Executive David Atkins made a purchase of 16,000 shares at 404.2p per share, while Terry Duddy, the group's non-excutive director, purchased
Read moreVectura enters into new agreement
3rd Aug 2011 12:28
Inhaled pharmaceutical products maker Vectura has agreed a new US collaboration with a leading international pharmaceutical company. Under the terms of this agreement, Vectura's unnamed partner will be responsible for the commercialisation and manufacture of Vectura's VR315 combination asthma/COPD
Read moreVectura trading in line with expectations
22nd Jul 2011 11:18
Inhaled pharmaceutical products maker Vectura said trading has been in line with expectations for the period from 1 April to 21 July, lifting investor sentiment. Vectura, which reported reduced losses for the year in May, reported revenue rose 7% to £42.9m, compared to the figures last year. The c
Read moreWednesday tips round-up: Yell, Vectura, Computacenter...
13th Jul 2011 06:45
Is there something to Yell about at last for yet another business struggling to cope with the impact of the internet revolution? asks the Independent. To be sure, investors in the company have had a torrid time in recent years. All of a sudden, however, the shares are showing signs of life. What's d
Read more